tiprankstipranks
Trending News
More News >
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558)
:1558
Hong Kong Market
Advertisement

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) Price & Analysis

Compare
0 Followers

1558 Stock Chart & Stats


YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H News

1558 FAQ

What was YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price range in the past 12 months?
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H lowest stock price was $7.92 and its highest was $17.74 in the past 12 months.
    What is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s market cap?
    YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s market cap is $12.65B.
      When is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s upcoming earnings report date?
      YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s upcoming earnings report date is Aug 22, 2025 which is in 8 days.
        How were YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s earnings last quarter?
        YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H released its earnings results on Mar 28, 2025. The company reported -$0.249 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.249.
          Is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H overvalued?
          According to Wall Street analysts YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pay dividends?
            YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pays a Annually dividend of $1.637 which represents an annual dividend yield of 10.31%. See more information on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H dividends here
              What is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate?
              YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H have?
              YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H has 653,767,700 shares outstanding.
                What happened to YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price movement after its last earnings report?
                YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H reported an EPS of -$0.249 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.69%.
                  Which hedge fund is a major shareholder of YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H?
                  Currently, no hedge funds are holding shares in HK:1558

                  YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Stock Smart Score

                  Company Description

                  YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H

                  YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) is a prominent pharmaceutical company primarily engaged in the research, manufacturing, and distribution of pharmaceutical products. Operating within the broader healthcare sector, the company's core offerings include both prescription and over-the-counter medications, with a particular focus on antiviral drugs and treatments for chronic diseases. The company is dedicated to the development of high-quality, innovative medical solutions that cater to the growing healthcare needs of its clientele.

                  YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) Earnings & Revenues

                  1558 Stock 12 Month Forecast

                  Average Price Target

                  $14.00
                  ▼(-11.84% Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","15":"$15","8.25":"$8.25","10.5":"$10.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,8.25,10.5,12.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Dec<br/>2024","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,13.483076923076922,13.526153846153846,13.569230769230769,13.612307692307692,13.655384615384616,13.698461538461538,13.741538461538461,13.784615384615384,13.827692307692308,13.87076923076923,13.913846153846153,13.956923076923077,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,13.483076923076922,13.526153846153846,13.569230769230769,13.612307692307692,13.655384615384616,13.698461538461538,13.741538461538461,13.784615384615384,13.827692307692308,13.87076923076923,13.913846153846153,13.956923076923077,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,13.483076923076922,13.526153846153846,13.569230769230769,13.612307692307692,13.655384615384616,13.698461538461538,13.741538461538461,13.784615384615384,13.827692307692308,13.87076923076923,13.913846153846153,13.956923076923077,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.68,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.18,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.67,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.74,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.96,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.14,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.35,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.75,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Shandong Xinhua Pharmaceutical Company Limited Class H
                  China Shineway Pharmaceutical Group Limited
                  Jacobson Pharma Corporation Limited
                  Consun Pharmaceutical Group Ltd.
                  China Traditional Chinese Medicine Holdings Co

                  Ownership Overview

                  2.59%94.24%
                  Insiders
                  2.59%
                  Mutual Funds
                  ― Other Institutional Investors
                  94.24% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis